Alliance Pharma launches nausea drug Xonvea in UK
The newly licensed Xonvea, which is a combination of doxylamine and pyridoxine, will be available across the country for women having NVP where conservative management was not successful.
Haisco Pharmaceutical Group has signed an exclusive licensing agreement granting US-based biotechnology company Nuvectis rights for two drug candidates in oncology and complement indications.
The facility, which includes development and manufacturing capabilities for novel respiratory products, complements the inhalation development expertise offered by the Recipharm team in Research Triangle Park, North Carolina.
In November 2014, Janssen signed an exclusive worldwide collaboration and license agreement with Geron for the development and commercialization of imetelstat in oncology, including hematologic myeloid malignancies. Janssen